- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Gaithersburg Today
By the People, for the People
GeneDx CEO Sells Over $2.9 Million in Shares
Insider trading activity at the genetic testing company
Apr. 3, 2026 at 8:28am
Got story updates? Submit your updates here. ›
Insider trading activity by GeneDx's CEO highlights the complex machinery of the financial industry.Gaithersburg TodayGeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 46,933 shares of the company's stock in a transaction on March 26th. The shares were sold at an average price of $63.17, resulting in a total transaction value of $2,964,757.61. This sale represents a 33.90% decrease in Stueland's ownership stake in GeneDx.
Why it matters
Insider trading activity, especially by a company's CEO, can provide valuable insights into management's views on the company's prospects and valuation. Significant insider sales can sometimes signal concerns about the company's future performance or stock price.
The details
The transaction was disclosed in a filing with the Securities and Exchange Commission. Following the sale, Stueland still owns 91,514 shares in the company, valued at approximately $5,780,939.38. Stueland has made several other large stock sales in recent months, including transactions in March, January, and December 2025.
- The shares were sold on Thursday, March 26th, 2026.
- Stueland also sold 17,179 shares on Monday, March 16th, 2026, and 25,459 shares on Wednesday, March 4th, 2026.
- In January 2026, Stueland sold 1,653 shares.
The players
Katherine Stueland
The CEO of GeneDx Holdings Corp., a clinical diagnostics company specializing in genetic and genomic testing.
GeneDx Holdings Corp.
A NASDAQ-listed clinical diagnostics company that offers a broad portfolio of genetic and genomic testing services.
What’s next
Investors will likely continue to monitor GeneDx's stock performance and any further insider trading activity by the CEO and other company executives.
The takeaway
The significant stock sales by GeneDx's CEO could raise questions about the company's future prospects and valuation, though insider trading activity alone does not necessarily indicate broader concerns. Investors should consider the CEO's motivations and the company's overall financial health when evaluating the significance of these transactions.
